Glimepiride can reduce inflammation in diabetes by decreasing markers like CRP and IL-6, potentially reducing complications like heart disease.

Glimepiride, used in type 2 diabetes, may lower inflammation by affecting cytokines and reducing insulin resistance, thus helping manage long-term complications.

Studies suggest that Glimepiride can mitigate inflammatory markers such as C-reactive protein and TNF-alpha in diabetic patients, improving overall health outcomes.